Eversept Partners, LP Alnylam Pharmaceuticals, Inc. Transaction History

Eversept Partners, LP

$1.26 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 08, 2023	BUY	$120.42 - $169.29 $3.14 Million - $4.42 Million	26,116 Added 49.4%	78,987 $11.5 Million
Q2 2022 Aug 15, 2022	BUY	$120.42 - $169.29 $3.14 Million - $4.42 Million	26,116 Added 49.4%	78,987 $11.5 Million
Q1 2022 Nov 08, 2023	BUY	$127.18 - $173.91 $6.72 Million - $9.19 Million	52,871 New	52,871 $8.63 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $2.21 Million - $3.02 Million	-17,369 Reduced 24.73%	52,871 $8.63 Million
Q4 2021 Nov 08, 2023	BUY	$159.56 - $209.29 $1.76 Million - $2.3 Million	11,007 Added 18.58%	70,240 $11.9 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $1.76 Million - $2.3 Million	11,007 Added 18.58%	70,240 $11.9 Million
Q3 2021 Nov 08, 2023	BUY	$169.75 - $207.73 $1.37 Million - $1.68 Million	8,097 Added 15.83%	59,233 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $1.37 Million - $1.68 Million	8,097 Added 15.83%	59,233 $11.2 Million
Q2 2021 Nov 08, 2023	SELL	$128.63 - $176.89 $3.83 Million - $5.27 Million	-29,801 Reduced 36.82%	51,136 $8.67 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $3.83 Million - $5.27 Million	-29,801 Reduced 36.82%	51,136 $8.67 Million
Q1 2021 Nov 08, 2023	BUY	$126.83 - $175.69 $10.3 Million - $14.2 Million	80,937 New	80,937 $11.4 Million
Q1 2021 May 13, 2021	BUY	$126.83 - $175.69 $10.3 Million - $14.2 Million	80,937 New	80,937 $11.4 Million
Q4 2019 Feb 13, 2020	SELL	$74.51 - $124.23 $6.86 Million - $11.4 Million	-92,040 Closed	0 $0
Q3 2019 Nov 08, 2023	BUY	$70.9 - $87.82 $347,410 - $430,317	4,900 Added 5.62%	92,040 $7.4 Million
Q3 2019 Nov 13, 2019	BUY	$70.9 - $87.82 $347,410 - $430,317	4,900 Added 5.62%	92,040 $7.4 Million
Q2 2019 Nov 08, 2023	BUY	$65.86 - $92.79 $1.56 Million - $2.19 Million	23,647 Added 37.24%	87,140 $6.32 Million
Q2 2019 Aug 13, 2019	BUY	$65.86 - $92.79 $5.74 Million - $8.09 Million	87,140 New	87,140 $6.32 Million
Q3 2018 Nov 14, 2018	SELL	$87.52 - $122.67 $5.56 Million - $7.79 Million	-63,493 Closed	0 $0
Q2 2018 Nov 08, 2023	SELL	$88.31 - $107.8 $1.36 Million - $1.66 Million	-15,400 Reduced 19.52%	63,493 $6.25 Million
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $1.36 Million - $1.66 Million	-15,400 Reduced 19.52%	63,493 $6.25 Million
Q1 2018 Nov 08, 2023	BUY	$115.92 - $148.54 $9.15 Million - $11.7 Million	78,893 New	78,893 $9.4 Billion
Q1 2018 May 14, 2018	BUY	$115.92 - $148.54 $9.15 Million - $11.7 Million	78,893 New	78,893 $9.4 Million

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

Capital World Investors Los Angeles, CA

16.5M
Shares

$4.2 Billion
0.73% of portfolio
Vanguard Group Inc Valley Forge, PA

12.6M
Shares

$3.21 Billion
0.06% of portfolio
Black Rock Inc. New York, NY

9.55M
Shares

$2.43 Billion
0.05% of portfolio
Capital Research Global Investors Los Angeles, CA

5.24M
Shares

$1.33 Billion
0.31% of portfolio
Wellington Management Group LLP Boston, MA

4.95M
Shares

$1.26 Billion
0.24% of portfolio

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account